Kamada Ltd. (NASDAQ:KMDA) Sees Significant Growth in Short Interest

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 56,800 shares, an increase of 61.8% from the February 28th total of 35,100 shares. Based on an average daily volume of 210,800 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company’s stock are sold short.

Analyst Ratings Changes

A number of research firms have recently issued reports on KMDA. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Kamada in a research report on Thursday, March 6th. StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th. Finally, Benchmark initiated coverage on Kamada in a report on Friday, March 21st. They set a “buy” rating and a $15.00 price objective for the company.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently modified their holdings of KMDA. NewEdge Advisors LLC boosted its position in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the last quarter. Aristides Capital LLC boosted its holdings in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 6,850 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Kamada in the fourth quarter valued at about $67,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Kamada during the third quarter valued at about $77,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Price Performance

Shares of NASDAQ KMDA traded down $0.08 during mid-day trading on Friday, reaching $6.75. 49,625 shares of the company’s stock traded hands, compared to its average volume of 79,188. The business has a 50-day simple moving average of $7.17 and a 200 day simple moving average of $6.32. The stock has a market cap of $387.99 million, a P/E ratio of 24.11, a PEG ratio of 0.97 and a beta of 0.97. Kamada has a 1-year low of $4.74 and a 1-year high of $9.16.

Kamada Dividend Announcement

The business also recently declared a — dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.